See our latest analysis for Amphastar Pharmaceuticals.
This recent run-up comes after a tough stretch, with Amphastar Pharmaceuticals’ share price still down over 23% year-to-date and its total shareholder return for the past year at negative 39%. The latest momentum suggests investors might be warming up to the company again. This could indicate renewed confidence in its growth prospects, even as it works through a longer-term recovery.
For those eyeing fresh opportunities in the sector, you can see the full list via our See the full list for free..
With shares still trading 16% below analyst price targets, yet surging lately, the key question for investors is whether Amphastar Pharmaceuticals remains undervalued or if the recent optimism already reflects all of its future growth potential.
Most Popular Narrative: 13% Undervalued
With Amphastar Pharmaceuticals closing at $27.83, the most widely followed narrative places its fair value much higher, hinting at upside if projections hold true. The market’s skepticism stands in sharp contrast to the optimism reflected in these calculations.
Expansion of domestic manufacturing, a diversified product pipeline, and strategic R&D investments position Amphastar for resilience, growth, and improved profitability in evolving pharmaceutical markets.
Want to know what big assumptions back this bullish price target? There is a bold growth thesis within the narrative, driven by ambitious revenue and profitability projections. Find out which financial leaps underpin this estimate and whether they could actually materialize.
Result: Fair Value of $32 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, persistent price pressure in generics and slow pipeline launches could undermine earnings growth. This raises questions about the reliability of today’s bullish outlook.
Find out about the key risks to this Amphastar Pharmaceuticals narrative.
Build Your Own Amphastar Pharmaceuticals Narrative
If you think there’s more to the story or want to see how the numbers stack up for yourself, it’s quick and easy to create your own perspective. Do it your way.
A great starting point for your Amphastar Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Ready for More Investment Ideas?
Great opportunities don’t wait. Use the Simply Wall Street Screener to tap into stocks with high potential, adaptable to any investment strategy or curiosity you have.
- Boost your portfolio’s income potential and zero in on market leaders by starting with these 14 dividend stocks with yields > 3%, offering robust yields above 3%.
- Capitalize on next-generation technology shifts by scanning these 27 AI penny stocks, at the forefront of artificial intelligence advancements.
- Take advantage of overlooked value by browsing these 880 undervalued stocks based on cash flows, identified as trading below their intrinsic cash flow estimates.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Amphastar Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com